A new analysis in a South American medical journal suggests GLP-1 medications may be linked to improvements. The full report has the details.
Recap by typeshit. Post by ABC News on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Biomea Fusion was set to release early results for its investigational obesity candidate on October 13, with shares at $1.44 in premarket trading.
Its October check of 21 US telehealth programs found compounded semaglutide at a $175 median, with a $79 sale low, counting memberships in the all-in price.
Loading…